

## Tamoxifen

### References to Supplementary Web Tables, Section 2

- Beiner ME, Finch A, Rosen B *et al.*; Hereditary Ovarian Cancer Clinical Study Group (2007). The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. *Gynecol Oncol*, 104:7–10 [doi:10.1016/j.ygyno.2006.08.004](https://doi.org/10.1016/j.ygyno.2006.08.004). PMID:16962648
- Bergman L, Beelen ML, Gallee MP *et al.* (2000). Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen. *Lancet*, 356:881–887 [doi:10.1016/S0140-6736\(00\)02677-5](https://doi.org/10.1016/S0140-6736(00)02677-5). PMID:11036892
- Bouchardy C, Verkooijen HM, Fioretta G *et al.* (2002). Increased risk of malignant mullerian tumor of the uterus among women with breast cancer treated by tamoxifen. *J Clin Oncol*, 20:4403 [doi:10.1200/JCO.2002.99.174](https://doi.org/10.1200/JCO.2002.99.174). PMID:12409344
- Braithwaite RS, Chlebowski RT, Lau J *et al.* (2003). Meta-analysis of vascular and neoplastic events associated with tamoxifen. *J Gen Intern Med*, 18:937–947 [doi:10.1046/j.1525-1497.2003.20724.x](https://doi.org/10.1046/j.1525-1497.2003.20724.x). PMID:14687281
- Chandanios E, Lindblad M, Jia C *et al.* (2006). Tamoxifen exposure and risk of oesophageal and gastric adenocarcinoma: a population-based cohort study of breast cancer patients in Sweden. *Br J Cancer*, 95:118–122 [doi:10.1038/sj.bjc.6603214](https://doi.org/10.1038/sj.bjc.6603214). PMID:16755290
- Chu W, Fyles A, Sellers EM *et al.* (2007). Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use. *Carcinogenesis*, 28:2139–2142 [doi:10.1093/carcin/bgm087](https://doi.org/10.1093/carcin/bgm087). PMID:17434921
- Cook LS, Weiss NS, Schwartz SM *et al.* (1995). Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. *J Natl Cancer Inst*, 87:1359–1364 [doi:10.1093/jnci/87.18.1359](https://doi.org/10.1093/jnci/87.18.1359). PMID:7658496
- Curtis RE, Boice JD Jr, Shriner DA *et al.* (1996). Second cancers after adjuvant tamoxifen therapy for breast cancer. *J Natl Cancer Inst*, 88:832–834 [doi:10.1093/jnci/88.12.832](https://doi.org/10.1093/jnci/88.12.832). PMID:8637050
- Curtis RE, Freedman DM, Sherman ME, Fraumeni JF Jr (2004). Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer. *J Natl Cancer Inst*, 96:70–74 [doi:10.1093/jnci/djh007](https://doi.org/10.1093/jnci/djh007). PMID:14709741
- Cuzick J, Powles T, Veronesi U *et al.* (2003). Overview of the main outcomes in breast-cancer prevention trials. *Lancet*, 361:296–300 [doi:10.1016/S0140-6736\(03\)12342-2](https://doi.org/10.1016/S0140-6736(03)12342-2). PMID:12559863
- Delozier T, Spielmann M, Macé-Lesec'h J *et al.*; Fédération Nationale des Centres de Lutte Contre le Cancer Breast Group (2000). Tamoxifen adjuvant treatment duration in early breast cancer: initial results of a randomized study comparing short-term treatment with long-term treatment. *J Clin Oncol*, 18:3507–3512. PMID:11032592
- Fisher B, Costantino JP, Wickerham DL *et al.* (2005). Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. *J Natl Cancer Inst*, 97:1652–1662 [doi:10.1093/jnci/dji372](https://doi.org/10.1093/jnci/dji372). PMID:16288118
- Fisher B, Dignam J, Bryant J *et al.* (1996). Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. *J Natl Cancer Inst*, 88:1529–1542 [doi:10.1093/jnci/88.21.1529](https://doi.org/10.1093/jnci/88.21.1529). PMID:8901851
- Katase K, Sugiyama Y, Hasumi K *et al.* (1998). The incidence of subsequent endometrial carcinoma with tamoxifen use in patients with primary breast carcinoma. *Cancer*, 82:1698–1703 [doi:10.1002/\(SICI\)1097-0142\(19980501\)82:9<1698::AID-CNCR16>3.0.CO;2-#](https://doi.org/10.1002/(SICI)1097-0142(19980501)82:9<1698::AID-CNCR16>3.0.CO;2-#). PMID:9576291
- Lavie O, Barnett-Griness O, Narod SA, Rennert G (2008). The risk of developing uterine sarcoma after tamoxifen use. *Int J Gynecol Cancer*, 18:352–356 [doi:10.1111/j.1525-1438.2007.01025.x](https://doi.org/10.1111/j.1525-1438.2007.01025.x). PMID:18334013
- Matsuyama Y, Tominaga T, Nomura Y *et al.* (2000). Second cancers after adjuvant tamoxifen therapy for breast cancer in Japan. *Ann Oncol*, 11:1537–1543 [doi:10.1023/A:1008383804811](https://doi.org/10.1023/A:1008383804811). PMID:11205460
- Metcalfe KA, Lynch HT, Ghadirian P *et al.* (2005). The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. *Gynecol Oncol*, 96:222–226 [doi:10.1016/j.ygyno.2004.09.039](https://doi.org/10.1016/j.ygyno.2004.09.039). PMID:15589605
- Mignotte H, Lasset C, Bonadona V *et al.*; Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) (1998). Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. *Int J Cancer*, 76:325–330 [doi:10.1002/\(SICI\)1097-0215\(19980504\)76:3<325::AID-IJC7>3.0.CO;2-X](https://doi.org/10.1002/(SICI)1097-0215(19980504)76:3<325::AID-IJC7>3.0.CO;2-X). PMID:9579567
- Newcomb PA, Solomon C, White E (1999). Tamoxifen and risk of large bowel cancer in women with breast cancer. *Breast Cancer Res Treat*, 53:271–277 [doi:10.1023/A:1006117220284](https://doi.org/10.1023/A:1006117220284). PMID:10369073

- Rutqvist LE, Johansson H; Stockholm Breast Cancer Study Group (2007). Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer. *Acta Oncol*, 46:133–145 [doi:10.1080/02841860601034834](https://doi.org/10.1080/02841860601034834). PMID:17453361
- Sasco AJ, Chaplain G, Amoros E, Saez S (1996). Endometrial cancer following breast cancer: Effect of tamoxifen and castration by radiotherapy. *Epidemiology*, 7:9–13 [doi:10.1097/00001648-199601000-00003](https://doi.org/10.1097/00001648-199601000-00003). PMID:8664408
- Srinivasan R, Yang YX, Rubin SC *et al.* (2005). Women with a prior diagnosis of breast cancer are not at an increased risk for subsequent colorectal cancer. *Am J Gastroenterol*, 100:2759–2764 [doi:10.1111/j.1572-0241.2005.00316.x](https://doi.org/10.1111/j.1572-0241.2005.00316.x). PMID:16393232
- Swerdlow AJ, Jones ME (2007). Ovarian cancer risk in premenopausal and perimenopausal women treated with Tamoxifen: a case-control study. *Br J Cancer*, 96:850–855 [doi:10.1038/sj.bjc.6603605](https://doi.org/10.1038/sj.bjc.6603605). PMID:17285129
- Swerdlow AJ, Jones ME; British Tamoxifen Second Cancer Study Group (2005). Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. *J Natl Cancer Inst*, 97:375–384 [doi:10.1093/jnci/dji057](https://doi.org/10.1093/jnci/dji057). PMID:15741574
- Ursic Vrscaj M, Kovacic J, Bebar S *et al.* (2001). Endometrial and other primary cancers after tamoxifen treatment of breast cancer – results of retrospective cohort study. *Eur J Obstet Gynecol Reprod Biol*, 95:105–110 [doi:10.1016/S0301-2115\(00\)00376-6](https://doi.org/10.1016/S0301-2115(00)00376-6). PMID:11267730
- van Leeuwen FE, Benraadt J, Coebergh JW *et al.* (1994). Risk of endometrial cancer after tamoxifen treatment of breast cancer. *Lancet*, 343:448–452 [doi:10.1016/S0140-6736\(94\)92692-1](https://doi.org/10.1016/S0140-6736(94)92692-1). PMID:7905955
- Yamazawa K, Miyazawa Y, Suzuki M *et al.* (2006). Tamoxifen and the risk of endometrial cancer in Japanese women with breast cancer. *Surg Today*, 36:41–46 [doi:10.1007/s00595-004-3126-5](https://doi.org/10.1007/s00595-004-3126-5). PMID:16378192